

December 20th, 2023

### **Luxna Announces Option Agreement with Servier**

Osaka, Japan, December 20th, 2023 - Luxna Biotech Co., Ltd. (President CEO: Hideaki Sato, Headquarters: Suita-shi, Osaka, Japan, hereinafter "Luxna") today announced that it has entered into an option agreement (hereinafter "Option Agreement") with Servier, a global pharmaceutical group, (President: Olivier Laureau, Headquarters: Suresnes, France, hereinafter "Servier") to grant an exclusive license to use Luxna's breakthrough xeno nucleic acid technology (hereinafter "Luxna XNAs Technology") in the field of neurological diseases.

Luxna and Servier entered into a collaboration agreement for drug discovery research in the field of neurological diseases in March 2023. Under that collaboration agreement, Luxna and Servier will work together to optimize specific antisense oligonucleotides (hereinafter "ASO") compounds directed against transformative therapeutic targets in neurological diseases using Luxna XNAs Technology. Due to the achievement of the first stage, Luxna is now eligible to receive milestone payment from Servier.

Under an Option Agreement, Luxna and Servier will now both continue the drug development of on-going transformative therapies and expand the strategic alliance between Luxna and Servier towards the initiation of similar collaborative drug discovery research on multiple target genes.

Upon successful achievement of next stage, Luxna will be eligible for further milestones and, Luxna and Servier will enter into a world-wide exclusive license agreement that will grant Servier the right to use Luxna XNAs Technology for its transformative programs. In this case, Luxna will receive an upfront payment, annual fees, and milestone payments based on the progress of the programs.

Hideaki Sato, President CEO of Luxna, commented as follows: "We have been pursuing the application of Luxna XNAs Technology to the field of neurological diseases and have enhanced our ASO drug discovery platform called LuxiAP™. We are very pleased that we have moved from collaborative drug discovery research to the Option Agreement which covers an expansion of our strategic alliance with Servier. The partnership with Servier will accelerate the development and practical application of oligonucleotide therapies using Luxna XNAs Technology."

#### About Luxna XNAs Technology

Luxna XNAs Technology collectively means an innovative nucleic acid group of AmNA™, scpBNA™, GuNA™ and 5'-CP™ originated in Professor Obika's laboratory at the Osaka University Graduate School of Pharmaceutical Sciences, Bioorganic Chemistry. Luxna XNAs Technology could make available ASOs with high activity and low toxicity, by taking advantage of its characteristics of strong binding to mRNA and/or reduced toxicity.

#### About Luxna Biotech Co., Ltd.

Luxna is a biotech founded to develop safer and more effective oligonucleotide therapies (OTs) for practical use using the drug discovery platform based on modified nucleic acids originated at Osaka University. Our purpose is to bring OTs for patients with difficult-to-treat diseases. We actively collaborate with several pharmaceutical companies in developing new and effective OTs as well as advancing our own.

#### Contact

Luxna Biotech Co., Ltd.

E-mail: [info@luxnabiotech.co.jp](mailto:info@luxnabiotech.co.jp) HP : <https://luxnabiotech.co.jp/>